The company claims that Krystexxa is now the first and only therapy available to address this unmet medical need.
Savient Pharma CEO John Johnson said since receiving FDA approval for Krystexxa, we have focused on preparing for a successful US launch.
"Our sales force has completed very thorough and extensive training. We are excited to deploy this highly talented and biologics experienced team into their territories," Johnson said.